From The Wall Street Journal's Health Blog : AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis drug long sold by Bayer. Why would Novartis want to sell somebody else’s years-old drug? Largely to gain experience in the MS marketplace as Novartis plots a future launch of the MS drug FTY720. “It’s a way to build a strong commercial organization and a strong medical organization ahead of FTY,” Novartis pharmaceuticals chief Joe Jimemez told the Health Blog recently. [snippet] Read the full blog entry ========== Note: Here is a reference to FTY720: Horga A, & Montalban X. (2008). FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev Neurother., 8(5) 699-714. Clinical Neuroinmunology Unit, Multiple Sclerosis Center of Catalonia (CEM-Cat), Vall d'Hebron University Hospital, Barcelona, Spain. FTY720 (fingolimod) ...
News about our knowledge of the brain and behavior
from Anthony Risser, Ph.D.